All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the Multiple Myeloma Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss patient cases on treatment with Cereblon E3 ligase modulator (CELMoDs). This recorded discussion was chaired by Paul Richardson and featured Sagar Lonial, María-Victoria Mateos, Heinz Ludwig, Hermann Einsele, Morie Gertz, Elena Zamagni, and Meral Beksac.
Patient case discussion on treating with CELMoDs
This session opened with a presentation from Paul Richardson in which they shared the mechanism of action, latest clinical data, and applications for CELMoDs in multiple myeloma. Richardson highlighted iberdomide and mezigdomide as novel agents and discussed the latest data from trials on their use both as monotherapies and in combination.
The panel discussed differences between the two agents, the incorporation of these drugs into the myeloma treatment landscape, and optimal combination treatments. The experts concluded by discussing the incidence of secondary malignancies associated with these agents and the applications of CELMoDs in extramedullary multiple myeloma.
To download this resource, click below.Download here
Mezigdomide + dexamethasone for the treatment of RRMM
Here, we summarize key safety and efficacy data from the phase I and subsequent phase II trials of mezigdomide plus dexamethasone therapy in patients with relapsed/refractory multiple myeloma.
How might the iberdomide safety profile be critical for its future applications?
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked,...
Subscribe to get the best content related to multiple myeloma delivered to your inbox